CRS/HIPEC significantly enhances survival for select low-grade appendiceal carcinoma patients with peritoneal and parenchymal metastases.

• Median overall survival (OS) for low-grade mucinous and non-mucinous patients after CRS/HIPEC was not reached, compared to 50 months for surgery alone and 26 months for systemic chemotherapy (p < 0.01).
• In multivariable analysis, CRS/HIPEC reduced mortality risk for low-grade mucinous (HR 0.48) and non-mucinous (HR 0.15) cases (p < 0.01).

Consider CRS/HIPEC for suitable low-grade cases to improve patient outcomes.